1 of 1
Story summary
- U.S. Trade Representative Jamieson Greer launched a Section 301 investigation into Germany’s drug pricing, noting €220 price gap for Jardiance between Germany and uninsured U.S. patients by September.
- German Health Minister Nina Warken is advancing a multibillion-euro savings package that raises rebates and price concessions for innovative medicines.
- German Chancellor Friedrich Merz said the government will provide information for probe but warned tighter price controls could strain health-insurance funds.
